Q: Can I get your assessment of NGEN? Can the fundamentals support a sustained move in this one? That is some major volume coming in on those up days! Thanks.
5i Research Answer:
Up more than 60% in four days, the volume is a nice confirmation of a possible trend. But there was no specific news other than the upcoming presentation of trial data in early June (this should not have been a surprise). We note it is just a Phase 1b/2a study, so, while important, is not enough to get approval of course. But...if results are good then certainly it is more positive than negative for continued development. But we don't have much to analyze here: no revenue, losses and negative cash flow. It all depends on clinical success, which of course can be very difficult to call. The pipeline is decent, and insiders own 9%, but this needs to be considered very high risk with such a big ramp up going into a presentation.